Nanoscope to Moderate Discussions at the 4th Annual Gene Therapy Comparability Summit

Nanoscope to Moderate Discussions at the 4th Annual Gene Therapy Comparability Summit

Dallas, February 14, 2024 — Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, is pleased to announce its role at the 4th Annual Gene Therapy Comparability Summit taking place February 13-15, 2024, in Boston. This year’s summit will focus on implementing effective comparability studies to overcome strategic and technical hurdles and expedite the approvals of novel gene therapies.

Samarendra Mohanty, PhD, President and Chief Scientific Officer of Nanoscope, will chair the event. In his presentation and in a session, Dr. Mohanty will offer insights into navigating process modifications and forward-thinking strategies in transitioning to commercially viable processes while ensuring comparability.

Presentation details are as follows:
Session: Innovations in Gene Therapy Process Development to Aid Comparability
Title: Fireside Chat: Navigating Process Changes and the Assurance of Comprehensive Testing to Minimize Challenges in Gene Therapy Comparability
Date: Wednesday, February 14, 2024
Time: 3:30 p.m. ET

Session: Delving into Analytical Challenges to Overcome Comparability Issues
Title: Navigating Challenges in CMC Package Submissions
Date: Thursday, February 15, 2024
Time: 11:30 a.m. ET

Nanoscope remains committed to pushing the boundaries of gene therapy to elevate patient outcomes and eagerly anticipates stimulating discussions with esteemed peers at this meeting.

For further details and to register, visit https://genetherapy-comparability.com/

About Nanoscope Therapeutics, Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy in patients with Stargardt disease (NCT05417126). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
[email protected]

On February 14, 2024   /   Nanoscope Press Release, Home Page  
Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186

  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Dr. Mohanty obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from the National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs an international conference on optogenetics. He is the winner of a 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.